Heat Biologics, Inc., a biopharmaceutical company, engages in the development of immunotherapies to activate patient’s immune system against cancer through T-cell activation and expansion.
Share Price & News
How has Heat Biologics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: HTBX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: HTBX's weekly volatility has decreased from 13% to 6% over the past year.
7 Day Return
1 Year Return
Return vs Industry: HTBX underperformed the US Biotechs industry which returned 25.9% over the past year.
Return vs Market: HTBX underperformed the US Market which returned 33% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Heat Biologics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall StHere's Why We're Not Too Worried About Heat Biologics' (NASDAQ:HTBX) Cash Burn Situation
6 months ago | Simply Wall StReflecting on Heat Biologics' (NASDAQ:HTBX) Share Price Returns Over The Last Five Years
Heat Biologics Fundamentals Summary
|HTBX fundamental statistics|
Is HTBX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|HTBX income statement (TTM)|
|Cost of Revenue||US$14.99m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-1.27|
|Net Profit Margin||-1,198.61%|
How did HTBX perform over the long term?See historical performance and comparison
Is Heat Biologics undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate HTBX's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate HTBX's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: HTBX is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: HTBX is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate HTBX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: HTBX is good value based on its PB Ratio (1.2x) compared to the US Biotechs industry average (3.1x).
How is Heat Biologics forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: HTBX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: HTBX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: HTBX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: HTBX's revenue (89.5% per year) is forecast to grow faster than the US market (9.8% per year).
High Growth Revenue: HTBX's revenue (89.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if HTBX's Return on Equity is forecast to be high in 3 years time
How has Heat Biologics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: HTBX is currently unprofitable.
Growing Profit Margin: HTBX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: HTBX is unprofitable, and losses have increased over the past 5 years at a rate of 16.7% per year.
Accelerating Growth: Unable to compare HTBX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: HTBX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).
Return on Equity
High ROE: HTBX has a negative Return on Equity (-22.77%), as it is currently unprofitable.
How is Heat Biologics's financial position?
Financial Position Analysis
Short Term Liabilities: HTBX's short term assets ($124.8M) exceed its short term liabilities ($3.4M).
Long Term Liabilities: HTBX's short term assets ($124.8M) exceed its long term liabilities ($5.0M).
Debt to Equity History and Analysis
Debt Level: HTBX is debt free.
Reducing Debt: HTBX has no debt compared to 5 years ago when its debt to equity ratio was 442.3%.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: HTBX has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: HTBX has sufficient cash runway for 2.6 years if free cash flow continues to reduce at historical rates of 7.1% each year.
What is Heat Biologics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate HTBX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate HTBX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if HTBX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if HTBX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of HTBX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Jeff Wolf (58 yo)
Mr. Jeffrey Alan Wolf, also known as Jeff, J.D., founded Heat Biologics, Inc. in August 2008 and has been its Chairman of the Board, Chief Executive Officer and President since August 2008. Mr. Wolf served...
CEO Compensation Analysis
Compensation vs Market: Jeff's total compensation ($USD6.42M) is above average for companies of similar size in the US market ($USD1.10M).
Compensation vs Earnings: Jeff's compensation has increased whilst the company is unprofitable.
Experienced Management: HTBX's management team is not considered experienced ( 0.7 years average tenure), which suggests a new team.
Experienced Board: HTBX's board of directors are considered experienced (4.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 19.7%.
Heat Biologics, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Heat Biologics, Inc.
- Ticker: HTBX
- Exchange: NasdaqCM
- Founded: 2008
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$157.972m
- Shares outstanding: 25.40m
- Website: https://www.heatbio.com
Number of Employees
- Heat Biologics, Inc.
- 627 Davis Drive
- Suite 400
- North Carolina
- United States
Heat Biologics, Inc., a biopharmaceutical company, engages in the development of immunotherapies to activate patient’s immune system against cancer through T-cell activation and expansion. Its gp96 platfor...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/22 00:20|
|End of Day Share Price||2021/09/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.